SPX3,911.74+116.01 3.06%
DIA315.02+8.28 2.70%
IXIC11,607.62+375.43 3.34%

Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program

Favorable tolerability with no grade 3/4 neutropenia and encouraging anti-tumor activity across Phase 1b monotherapy expansion Combinability with CDK4/6i palbociclib demonstrated across initial dose escalation

Benzinga · 06/09/2022 07:38
  • Favorable tolerability with no grade 3/4 neutropenia and encouraging anti-tumor activity across Phase 1b monotherapy expansion

  • Combinability with CDK4/6i palbociclib demonstrated across initial dose escalation cohorts, including no dose limiting toxicities and no induced metabolism of palbociclib
  • Rapidly advancing the development of OP-1250 for ER+ / HER2- breast cancer with pivotal monotherapy study planned for 2023 initiation